论文部分内容阅读
在以四氯化碳复制大鼠肝纤维化过程中，分别于实验第1d（四甲基吡嗪预防组）、第31d（四甲基吡嗪治疗组）投予四甲基吡嗪，并用葡萄糖作为平行对照。结果发现：四甲基吡嗪预防组的门脉压、肝内胶原含量与正常对照组相比，无显著性差异（P＞0．05）。四甲基吡嗪治疗组的上述两项指标虽高于正常对照组，但明显低于葡萄糖组（P＜0．01）。四甲基吡嗪预防组和治疗组肝功能指标明显好于葡萄糖组。四甲基吡嗪具有预防和延缓鼠肝纤维化发生及发展的作用。
In the process of carbon tetrachloride-induced rat liver fibrosis, tetramethylpyrazine was administered on the first day (tetramethylpyrazine prophylaxis group) and on the 31 st day (tetramethylpyrazine group), respectively, Glucose as a parallel control. The results showed that portal vein pressure and intrahepatic collagen content in tetramethylpyrazine group were not significantly different from those in normal control group (P> 0.05). Although the above two indexes of tetramethylpyrazine group were higher than those of normal control group, they were obviously lower than that of glucose group (P <0.01). Tetramethylpyrazine prevention group and treatment group was significantly better than the liver function indicators glucose group. Tetramethylpyrazine can prevent and delay the occurrence and development of rat liver fibrosis.